Skip to main content
ABIONYX Pharma logo

ABIONYX Pharma — Investor Relations & Filings

Ticker · ABNX ISIN · FR0012616852 LEI · 969500785J7VIC5YPC96 PA Manufacturing
Open in API
Filings indexed 657 across all filing types
Latest filing 2026-02-04 Share Issue/Capital Cha…
Country FR France
Listing PA ABNX

About ABIONYX Pharma

https://abionyx.com/en/

ABIONYX Pharma is a new-generation biotechnology company that develops innovative therapies for indications with no effective or existing treatments. The company leverages extensive expertise in lipid metabolism and is a leader in recombinant apolipoprotein A-I (apoA-I), the primary protein of High-Density Lipoprotein (HDL). Its core technology platform utilizes apoA-I to create novel biotherapies and HDL vectors for targeted drug delivery. Key therapeutic areas of focus include critical illnesses such as sepsis, as well as renal and ophthalmological diseases. The company's strategy involves an integrated approach, combining biotherapy with diagnostics to address complex medical conditions with high unmet needs.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Share Issue/Capital Change Classification · 95% confidence The document is a monthly disclosure of total voting rights and share capital, citing Article L233-8-II of the French Commercial Code and AMF regulations. This type of disclosure is a standard regulatory requirement for companies listed on Euronext Paris to inform the market about changes in share capital and voting rights. Since it does not fit into specific categories like 'Major Shareholding Notification' (which tracks individual investors) or 'Share Issue' (which focuses on the act of issuance), it falls under the general regulatory filing category for periodic disclosures of capital structure.
2026-02-04 English
Informations privilégiées / Autres communiqués
Share Issue/Capital Change Classification · 95% confidence The document is a standard regulatory disclosure regarding the total number of voting rights and shares composing the share capital of ABIONYX Pharma. This type of filing is a mandatory periodic disclosure required by the AMF (French Financial Markets Authority) to inform the public of changes in capital structure and voting rights. It does not represent a major shareholding notification (MRQ), a share issue (SHA), or a transaction in own shares (POS), but rather a routine regulatory update on capital composition. Therefore, it falls under the general regulatory filing category.
2026-02-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 95% confidence The document is a monthly statement of total voting rights and shares forming the company's share capital, as required by Article L233-8-II of the French Commercial Code and Article 223-16 of the AMF General Regulations. This type of disclosure is a standard regulatory requirement for listed companies to inform the market about their capital structure and voting rights, which falls under the category of general regulatory announcements.
2026-01-28 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 95% confidence The document is a standard regulatory disclosure from ABIONYX Pharma regarding the total number of shares and voting rights as of a specific date (December 31, 2025). This type of filing is a mandatory periodic disclosure required by the AMF (French Financial Markets Authority) for listed companies to inform the public of their capital structure for threshold crossing calculations. It does not fit into specific categories like 'Share Issue' (SHA) or 'Major Shareholding' (MRQ) as it is a general disclosure of the company's own capital composition. Therefore, it falls under the 'Regulatory Filings' (RNS) category as a miscellaneous regulatory announcement.
2026-01-28 French
Inside Information / Other news releases
Report Publication Announcement Classification · 98% confidence The document is a press release from ABIONYX Pharma announcing its financial calendar for the year 2026. It lists upcoming dates for financial results and activity updates. Since it is an announcement regarding the timing and schedule of future report publications rather than the reports themselves, it falls under the category of a Report Publication Announcement.
2026-01-23 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 100% confidence The document is a press release from ABIONYX Pharma announcing its financial communication calendar for the year 2026. It lists future dates for earnings releases and activity updates. Since it is an announcement regarding the timing and schedule of future report publications rather than the reports themselves, it falls under the 'Report Publication Announcement' category.
2026-01-23 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.